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Abstract
Background: This study was conducted to assess the efficacy and acceptability of using a multi-level pregnancy
test (MLPT) combined with telephone follow-up for medical abortion in Tunisia, where the majority of providers are
midwives.
Methods: Four hundred and four women with gestational age ≤ 70 days’ LMP seeking medical abortion at six
study sites were enrolled in this open-label trial. Participants administered a baseline MLPT at the clinic prior to
mifepristone administration and were asked to take a second MLPT at home and to call in its results before
returning the day of their scheduled follow-up visit 10-14 days later.
Results: Almost all women with follow-up (97.1 %, n = 332/342) had successful abortions without the need for surgical
intervention. The MLPT worked extremely well among women ≤63 days’ LMP in ruling out ongoing pregnancy
(negative predictive value (NPV) =100 % (n = 298/298)) and also detecting women with ongoing pregnancies
(sensitivity = 100 %; 2/2) as needing follow-up due to non-declining hCG. Among women 64-70 days’ LMP, the test
also worked well in ruling out ongoing pregnancy (NPV = 96.9 % (n = 31/32) but not as well in terms of sensitivity
(50 %), with only one of two ongoing pregnancies detected by MLPT as needing follow-up. Most women (95.1 %)
found the MLPT to be very easy or easy to use and would consider using the MLPT again (97.4 %) if needed.
Conclusions: Self-administered pre and post MLPT are very easy for women to use and accurate in assessing medical
abortion success up to 63 days’ LMP. MLPT use for medical abortion follow-up has the potential to facilitate task
sharing services and eliminate the burden of routine in-person follow-up visits for the large majority of women.
Additional research is warranted to explore the accuracy of the MLPT in identifying ongoing pregnancy among
women with gestational ages > 63 days.
Trial registration: This study was registered on May 13, 2010, on clinicaltrials.gov as NCT01150279.
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Background
Medical abortion follow-up typically involves a return to
the medical facility for evaluation of abortion status
using clinical exam and/or ultrasound. For the vast ma-
jority of women who will have a successful completion
without the need for any additional care, a return to the
clinic is unnecessary and only serves to add to time and
cost burdens [1]. In addition, rates of loss to follow-up
are often high, especially in settings like Tunisia that
have over 15 years of experience providing medical abor-
tion and where women and providers have confidence in
the method’s efficacy (personal communication, Tunisia’s
National Office for the Family Planning and Population
(ONFP)). A multi-level pregnancy test (MLPT) admin-
istered by women at home to confirm abortion success
is a promising alternative to streamline care and elim-
inate the burden of routine in-person follow-up for all
women [2–5].
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Multi-level pregnancy tests (MLPT), also known as
semi-quantitative pregnancy tests (SQPT), provide infor-
mation about urine hCG levels by using a series of desig-
nated hCG ranges. The use of such tests sequentially, first
in-clinic prior to initiating abortion treatment and then at
home 7–14 days later, allows women to self-assess the
need to return to the clinic. In two recent studies, all
women with ongoing pregnancies (n = 12/12) had steady
or increasing hCG levels with their follow-up MLPTs
[6, 7]. The test’s specificity (the proportion of women
without ongoing pregnancy who had a decrease in hCG
level) was also shown to be quite high (93.6 %, n = 573/
612); the proportion of women flagged by the test to return
unnecessarily (due to a false positive test result) was very
low. Studies in many settings have shown the technology to
be effective and acceptable to women and providers [6–9].
Integrating this technology into medical abortion ser-
vices could eliminate the routine follow-up visit, making
medical abortion a single visit service for most women.
It also has tremendous potential for decentralizing care
and expanding access to medical abortion, particularly
where there is limited or no ultrasound capacity. As
contraceptives and related counseling are typically of-
fered during the follow-up visit or once a complete abor-
tion is confirmed, the integration of MLPT might
require a shift in provider practices so that almost all
methods are offered at the initial visit as already recom-
mended by the World Health Organization (WHO) [10].
In line with new WHO guidelines seeking to expand the
role of health workers in medical abortion provision, the
MLPT could play a potentially important role in granting
women greater autonomy while allowing for task-
sharing services to lower levels of care, where services
may be offered by a range of providers with or without
ultrasound [11].
We conducted this study to assess the efficacy and ac-
ceptability of using a multi-level pregnancy test (MLPT)
combined with telephone follow-up for medical abortion
in Tunisia, where the majority of providers are mid-
wives. While previous MLPT studies primarily focused
on physician providers [6–9], the vast majority of med-
ical abortion providers in Tunisia are midwives in re-
gional reproductive health centers. As early medical
abortion regimens have already been shown to be safe
and effective beyond 9 weeks LMP [12], we extended the
gestational age in this study to allow for enrollment be-
yond 63 days’ LMP. We also sought to evaluate the feasi-
bility and uptake of contraceptive methods to women at
the initial visit.
Methods
This was an open label prospective study. Women pre-
senting for medical abortion ≤ 70 days’ LMP at 6 study
sites that routinely provide medical abortion were invited
to participate in the study. Sites included 4 ONFP health
centers in Nabeul, Sousse, Ben Arous and Hamam Lif,
one large maternity hospital (La Rabta Maternity Hos-
pital), and a private clinic in Tunis (Clinique du Parc). Ex-
cept at the private clinic, providers at all sites were
primarily midwives offering eligibility screening, counsel-
ing and follow-up. Vaginal ultrasound was commonly per-
formed at initial visit for gestational age dating, usually by
an ultrasound technician. Eligibility criteria included being
eligible for mifepristone-misoprostol medical abortion,
agreeing to provide MLPT results by phone to a study co-
ordinator and to return for standard follow-up visit, and
willingness to provide telephone number for follow-up.
Ethical approval was given by the Ethics Committee of La
Rabta Maternity Hospital and by the Stanford University
Institutional Review Board, and all participants provided
written informed consent. This study was registered on
clinicaltrials.gov as NCT01150279.
Before taking 200 mg mifepristone at the clinic, par-
ticipants were asked to take a baseline MLPT and re-
ceived counseling on how to self-administer the test
again for follow-up and interpret the results. This study
used the dBest® (Ameritek; Seattle, Washington) semi-
quantitative pregnancy test that has five designated
hCG ranges: 25-99, 100-499, 500-1,999, 2000-9,999,
and ≥10,000 mIU/mL. Women were given 400 mcg
sublingual misoprostol to take on day 2 and a second
test to be self-administered at home on the day of their
scheduled follow-up visit 10-14 days later. Women
were asked to phone in the results to a study coordin-
ator before presenting to the clinic. They were also
given written instructions explaining how to use the
test, with pictures of possible MLPT results. All women
were provided with family planning counseling and of-
fered a choice of method at the initial visit and again at
follow-up.
Women who did not call in their results on the morn-
ing of their scheduled appointment, and/or who missed
their appointment, were telephoned by the coordinator
and asked about their results and to return. The coord-
inator also documented any reports of unscheduled
visits or interventions, including any conducted else-
where. Upon arrival at the clinic, each woman was inter-
viewed and seen by a provider to assess abortion status
using standard clinical means, usually ultrasound done
by a technician in these facilities. Women who returned
but had not taken the follow-up test were given another
test to self-administer at the clinic before seeing the pro-
vider. All other standard care for early medical abortion
was offered to the women as per clinic procedures.
We aimed to enroll at least 400 women in this study to
allow providers in each site adequate experience with the
technology. Outcomes included the test’s performance, in-
cluding its negative predictive value (the proportion of
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women whose MLPT results correctly ruled out ongoing
pregnancy) and its sensitivity (the proportion of those
with ongoing pregnancies correctly identified as needing
follow-up based on a steady or increasing hCG bracket).
We also examined the proportion of women who com-
pleted telephone follow-up, and women’s acceptability, in-
cluding their willingness to use the test in the future. As
this model in programs would virtually eliminate most
follow-up visits, we also collected data on the proportion
of women who selected a family planning method at the
initial visit as well as which methods they were actually
provided at initial visit and follow-up. All analyses were
conducted using SPSS version 19 (IBM, Armonk, NY,
USA) and STATA version 11 (StataCorp, College Station,
TX, USA).
Results
Four hundred and four women were enrolled in the
study between March 2013 and March 2014. Patient
flow is presented in Fig. 1 and participant characteristics
are presented in Table 1. MLPT outcomes as compared
to clinical assessment were analyzed for all but the 63
women who did not administer the second test (n = 5)
or who were lost to follow-up at study end (n = 58).
Almost all women with follow-up (97.1 %, n = 332/342)
had successful abortions without the need for surgical
intervention (Table 2). There were 4 ongoing pregnancies
diagnosed by providers among women who returned.
Three of these women (75.0 %) were detected as needing
to return for evaluation by steady MLPT readings of ≥
10,000 at both initial and follow-up. One of these three
women returned to the clinic three days after taking the
mifepristone as she felt she was still pregnant. The fourth
ongoing pregnancy, in a woman with an initial pregnancy
of 67 days’ LMP, was not detected by the MLPT which
showed a decline in hCG (from 2,000-9,999 to 100-499).
Upon return the woman reported that she believed she
was still pregnant despite the MLPT, as there was no ex-
pulsion as she had been counselled. There were five add-
itional women with a follow-up MLPT result of ≥
10,000 who did not have ongoing pregnancy; 3 of these
women had complete abortions and 2 had incomplete
abortions at first follow-up.
Three hundred and forty-one women had both abor-
tion outcome and follow-up MLPT data and were in-
cluded in the analysis of the test’s performance (Table 3).
The proportion of women with hCG decline who did
not have an ongoing pregnancy (the negative predictive
Fig. 1 Enrollment and participation flowchart
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value) was 100 % (n = 298/298) among women ≤63 days’
LMP and 96.9 % (n = 31/32) among women 64–70 days’
LMP. The sensitivity of the follow-up MLPT in identify-
ing the need for further evaluation (the percentage of
women with an ongoing pregnancy who had a steady or
increase in hCG range) was 100 % (n = 2/2) among
women ≤63 days’ LMP and 50.0 % (n = 1/2) among
women 64–70 days’ LMP.
Three hundred and forty eight women (86.1 % of
enrollees) completed their telephone follow-up call be-
fore their follow-up visit (Table 4). All but one (99.7 %)
had taken the MLPT at home. Most women (95.1 %)
found the MLPT to be very easy or easy to use. Only 4
women (1.2 %) thought it was difficult or very difficult.
All but one woman (99.7 %) found the provider instruc-
tions and information sheet to be useful. Most women
would consider using the MLPT again (97.4 %) and
would recommend it to a friend (97.7 %) for abortion
follow-up. Following the call, the majority of women
(91.7 %, n = 319) went on to attend their in-clinic
follow-up as scheduled.
Table 1 Clinical participant characteristics: mean ± SD (range)
or % (n)
n = 404




Primary (1–6) 20.3 (82)
Secondary (7–12) 46.1 (186)
University or higher 30.4 (123)










Table 2 Medical abortion outcomes: % (n)
n = 342
Medical abortion outcome at study enda
Successb 97.1 (332/342)
Surgical interventionc 2.9 (10/342)
Ongoing pregnancy 1.2 (4/342)
Incomplete abortion at study end 0.6 (2/342)
Medically necessary 0.9 (3/342)
Woman’s preference 0.3 (1/342)
aDoes not include 62 women who were lost to follow-up, 4 of whom had
incomplete abortions at first follow-up and did not return for
extended follow-up
b9 of these women were determined to be complete by phone
cSurgical intervention was done prior to scheduled follow-up for 1 woman
with ongoing pregnancy, the 3 women with medically necessary intervention,
and the woman who chose intervention
Table 3 MLPT results by gestational age: % [95 % CI*] (n)
n = 341a
Proportion of women with a decline
in hCG who did not have ongoing
pregnancy (negative predictive value)
≤ 63 days gestation 100.0 [98.8–100.0] (298/298)
64–70 days gestation 96.9 [83.8–99.9] (31/32)
Proportion of women with ongoing
pregnancy whose follow-up MLPT
indicated steady or increasing
hCG (sensitivity)
≤ 63 days gestation 100.0 [15.8–100.0] (2/2)
64–70 days gestation 50.0 [1.3–98.7] (1/2)
Proportion of women with steady
or increasing hCG who had
ongoing pregnancy (positive
predictive value)
≤ 63 days gestation 20.0 [2.5–55.6] (2/10)
64–70 days gestation 100.0 [2.5–100.0] (1/1)




≤ 63 days gestation 97.4 [94.9–98.9] (298/306)
64–70 days gestation 100.0 [88.8–100.0] (31/31)
*95 % CIs calculated using exact binomial confidence intervals
aWomen with follow-up MLPT data and abortion outcome at 1st follow-up; 2
of the follow-up MLPTs were conducted in the clinic; the rest were conducted
by the woman at home
Table 4 Experience of MLPT and telephone follow-up: % (n)
n = 348a
Took MLPT at home 99.7 (347)
Attended scheduled clinic follow-up after call 91.4 (318)
Ease of using MLPT at home (n = 346)
Very easy or easy 95.1 (329)
Neither easy nor difficult 3.8 (13)
Difficult or very difficult 1.2 (4)
Participant found provider explanation and
instruction sheet useful
99.7 (345/346)
Participant would consider using this test again 97.4 (335/344)
Participant would recommend MLPT to a friend
if needed to determine pregnancy status at home
97.7 (335/343)
aDoes not include the 56 women who did not have a follow-up call per protocol
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Most women (95.0 %, n = 384) selected a contraceptive
method at the initial clinic visit and half (51.5 %, n = 206)
received a method that day (Fig. 2). Despite encourage-
ment to providers to offer women all eligible methods
on day 1, women who selected implants or injectables
were not given the method until the follow-up visit. In
addition, given that an IUD cannot be inserted until
the abortion is complete, women who selected an IUD
were told at the initial visit that it could not be pro-
vided that day.
Discussion
As shown in previous studies, the MLPT’s sensitivity in
identifying the need for further evaluation among women
with ongoing pregnancy was very high among women ≤
63 days’ LMP [6, 7]. The accuracy of the MLPT in identi-
fying this need at > 63 days has not yet been demon-
strated, and in this study the MLPT failed to signal the
need for additional follow-up among one of the two on-
going pregnancies in this gestational age range. Another
failure in detection in a women 68 days’ LMP occurred in
a similar study carried out in Mexico around the same
time as this study (manuscript in submission). There is
some biological plausibility for this failure since hCG be-
gins to decrease beyond the 9th week of pregnancy [13].
Phone call compliance and acceptability were both very
high in this study, demonstrating that self-administered
MLPT at home followed by telephone follow-up to report
results to providers works very well for medical abortion
follow-up. Integrating this approach into routine service
delivery would allow the majority of women to avoid an
unnecessary clinic visit and help reduce the burden on
health systems. Further studies are being planned to assess
women’s ability to interpret the MLPT results without
conferring with a provider.
To better understand the implications of the single visit
medical abortion model on postabortion family planning
uptake, we encouraged providers to provide women with
all feasible methods at initial visit; however, providers
remained reluctant to shift practices and allow women to
receive implants and injectables on the day of mifepris-
tone administration as is suggested by WHO guidelines
[10]. Although this trend may have been influenced by
our study design that included routine follow-up to assess
outcome, in reality, a large proportion of women do not
return for their follow-up after medical abortion. Provider
reticence about “quick starting” implants and injectable
on day 1 seem to be mostly due to concerns about poten-
tially decreasing the efficacy of medical abortion drugs
and potentially increasing side effects, particularly bleed-
ing experienced by women. In addition to WHO’s recent
guidelines, of help in addressing these concerns may be
the results from recent research showing that etonogestrel
implants inserted at time of mifepristone do not decrease
medical abortion efficacy [14]; results from a similar study
examining the impact of IM dmpa are expected soon.
While home use of the MLPT has shown to be success-
ful, the biggest challenge to its introduction and systematic
use in Tunisia and other settings remains the lack of avail-
ability of a commercially available product. While high sen-
sitivity pregnancy tests are readily available in most
settings, their potential in medical abortion follow-up is
more limited, as they can take much longer to be of use in
detecting postabortion hcg drops [15]. Several MLPT de-
vises have been developed and may be marketed soon; in
anticipation of potential products becoming more widely
available in the near future, additional research should fur-
ther examine how to maximize the potential of MLPT to
improve the quality and reach of medical abortion. For ex-
ample, in Tunisia, follow-up has routinely been done 2
weeks after mifepristone, but new research suggests that
the MLPT can be used significantly earlier: up to two-
thirds of women could know if they need to return to the
clinic by 4 days after initial visit [15]. Many women prefer
to know sooner than two weeks as that may feel like a very
long time to wait. Future research should also explore
Pills Implant IUD Condoms Injectable Other
Selected Day 1 (N=384) 41.7% 19.8% 16.7% 14.8% 5.5% 1.6%
Received Day 1 (N=206) 71.8% 0.0% 0.0% 27.7% 0.0% 0.5%












Fig. 2 Post-abortion contraception at initial and follow-up visits
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how many tests women should be given (i.e., the potential
tradeoff of having some women know sooner (by taking
the test at day 4), knowing that some will need to take a
second test at day 7), and the ideal timeframe for tak-
ing them. In addition, the use of this test following
misoprostol-alone protocols should be explored, given
the significantly higher liklihood of ongoing pregnancy
[16, 17]. Where women have no access to mifepristone
due to lack of commercial availability or stock-outs, as is
not uncommon in Tunisia and other settings, the MLPT
may have an even greater importance for women using a
misoprostol-alone regimen. Finally, future service delivery
models integrating MLPT should explore the role of sim-
ple mobile technologies (automated phone systems, text
messaging, etc.) for facilitating remote reporting of
women’s results where follow-up remains required by
health systems and eventually, eliminating the need for
any follow-up entirely given that women can easily use
these tests.
There were limitations to this study that impeded add-
itional conclusions. First, as all women were asked to re-
turn to the clinic to compare their test result with
provider assessment, it does not assess women’s ability to
interpret the test on their own to determine if follow-up is
needed. In addition, as there is no MLPT currently on the
market and women were asked to both make a telephone
call and return to the clinic routinely in this study, it’s dif-
ficult to address the actual system burden/cost implica-
tions of integrating this technology as an option for
follow-up at this time. Finally, as discussed above, the
number of women enrolled who were > 63 days’ gestation
was small, therefore reducing our ability to make any con-
clusions about the use of the test in the 10th week.
Conclusions
The introduction of MLTP for at-home follow-up for
women seeking medical abortion has positive implica-
tions for both women and health systems. As this and
other clinical studies have demonstrated, the majority of
women who have medical abortion require very little
further care [18]. While some may argue that any rou-
tine follow-up of medical abortion is unnecessary, this
technology is perhaps a more palatable and acceptable
approach that can allay provider and women’s concerns
about the small probability of failure without the burden
of in-person follow-up or ultrasound. Despite the in-
creasing availability of ultrasound, it can be argued that
its routine use for services has become more problem-
atic than its value, often resulting in time-consuming
hurdles for women and possibly leading to higher rates
of intervention [19]. For example, in Tunisia, it is not
uncommon for women to have to wait hours at the
follow-up visit to get an ultrasound before even seeing a
provider for follow-up; this may be one reason that
many chose not to return for the follow-up appointment
and why they appreciate the test. As with medical abor-
tion, MLPT technology has great potential to make abor-
tion services simpler and more accessible for women, yet
the degree to which it can achieve this potential is also
largely dependent on the will of health systems and pro-
viders to engage and trust women with their own care.
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